Characterization of the differential immune oncologic profile and the histological pattern of inflammation in relation to the soluble immune biomarker Sema4D can provide a translational aspect that can further enhance our understanding and stratification of HNSCC patients. This evidence concerns the gene SEMA4D and head and neck squamous cell carcinoma.